Applicant: Robert J. Steffan et al.

Serial No.: 10/733,507

Filed: December 10, 2003

Page : 3 of 12

## Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

## Listing of Claims:

1. (Currently Amended) Antiatherosclerotic agents agent represented by Formulas I or II:

wherein

R is

wherein  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{13}$ , and  $R_{14}$  are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

Applicant: Robert J. Steffan et al. Attorney's Docket No.: 16156-031001 / AHP97254

Serial No.: 10/733,507

Filed: December 10, 2003

Page : 4 of 12

R<sub>6</sub>, and R<sub>7</sub> are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or CH<sub>2</sub>COOR<sub>8</sub>, where R<sub>8</sub> is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

 $R_1$  is hydrogen or a lower alkyl of 1-6 carbon atoms;  $R_2$ ,  $R_3$ , and  $R_4$  are each, independently, hydrogen or halogen; and  $R_5$  is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

# 2. (Currently Amended) The antiatherosclerotic agent of claim 1, wherein:

R is

$$R_{6}$$
  $R_{7}$   $R_{9}$   $R_{10}$   $R_{10}$ 

wherein:

R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or lower alkyl of 1 to 6 carbon atoms;

 $R_6$  and  $R_7$  are, each independently, lower alkyl of 1 to 6 carbon atoms; and X is O or S;

R<sub>1</sub> is hydrogen;

 $R_2$ ,  $R_3$ , and  $R_4$  are each, independently, hydrogen or halogen; and  $R_5$  is a lower alkyl of 1 to 6 carbon atoms;

Attorney's Docket No.: 16156-031001 / AHP97254 Applicant: Robert J. Steffan et al. Serial No.: 10/733,507 : December 10, 2003 Filed : 5 of 12 Page or a pharmaceutically acceptable salt thereof. (Canceled) 3. (Canceled) 4. (Canceled) 5. (Canceled) 6. (Canceled) 7. (Canceled) 8. 9. (Canceled) (Canceled) 10. (Canceled) 11. (Canceled) 12. 13. (Canceled) (Withdrawn) The compound of claim 1, which is 1-(5-chloro-2-methyl-phenyl)-3-(3-14. methyl-isothiazol-5-yl)-thiourea. 15. (Canceled) (Canceled) 16. 17. (Canceled

Applicant: Robert J. Steffan et al.

Serial No.: 10/733,507

Filed: December 10, 2003

Page : 6 of 12

- 18. (Canceled)
- 19. (Canceled)
- 20. (Canceled)
- 21. (Canceled)
- 22. (Canceled)
- 23. (Canceled)
- 24. (Canceled)
- 25. (Canceled)
- 26. (Canceled)
- 27. (Canceled)
- 28. (Currently Amended) A pharmaceutical composition, which comprises an antiatherosclerotic agent represented by Formula I or II:

$$\begin{array}{c|c} R_2 & CH_3 & R_1 \\ \hline R_3 & N & N \\ \hline R_4 & H & S \end{array}$$

]

II

wherein

R is

Applicant: Robert J. Steffan et al. Attorney's Docket No.: 16156-031001 / AHP97254

Serial No.: 10/733,507

Filed: December 10, 2003

Page : 7 of 12

wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

 $R_6$ , and  $R_7$  are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or  $CH_2COOR_8$ , where  $R_8$  is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;

R2, R3, and R4 are each, independently, hydrogen or halogen; and

R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof in association or combination with a pharmaceutically acceptable carrier.

Applicant: Robert J. Steffan et al.

Serial No.: 10/733,507

Filed: December 10, 2003

Page : 8 of 12

# 29. (New) A compound represented by Formulas I or II:

wherein

R is

$$R_{10}$$
 $R_{10}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{14}$ 
 $R_{14}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{14}$ 

wherein  $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{13}$ , and  $R_{14}$  are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

 $R_6$ , and  $R_7$  are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or  $CH_2COOR_8$ , where  $R_8$  is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;

R2, R3, and R4 are each, independently, hydrogen or halogen; and

Applicant: Robert J. Steffan et al. Attorney's Docket No.: 16156-031001 / AHP97254

Serial No.: 10/733,507

Filed: December 10, 2003

Page : 9 of 12

R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms; or a pharmaceutically acceptable salt thereof.

## 30. (New) The compound of claim 29, wherein:

R is

$$R_{6}$$
  $R_{7}$   $R_{9}$   $R_{10}$   $R_{10}$ 

wherein:

 $R_9$ ,  $R_{10}$ ,  $R_{11}$ ,  $R_{12}$ ,  $R_{13}$ , and  $R_{14}$  are each, independently, hydrogen or lower alkyl of 1 to 6 carbon atoms;

 $R_6$  and  $R_7$  are, each independently, lower alkyl of 1 to 6 carbon atoms; and X is O or S;

R<sub>1</sub> is hydrogen;

 $R_2$ ,  $R_3$ , and  $R_4$  are each, independently, hydrogen or halogen; and  $R_5$  is a lower alkyl of 1 to 6 carbon atoms;

or a pharmaceutically acceptable salt thereof.

31. (New) The compound of claim 29, which is 1-(5-chloro-2-methyl-phenyl)-3-(3-methyl-isothiazol-5-yl)-thiourea.

Applicant: Robert J. Steffan et al.

Serial No.: 10/733,507

Filed: December 10, 2003

Page : 10 of 12

# 32. (New) A pharmaceutical composition, which comprises a compound represented by Formula I or II:

wherein

#### R is

$$R_{10}$$
 $R_{10}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{14}$ 
 $R_{14}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{18}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R_{15}$ 
 $R_{16}$ 
 $R_{17}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{19}$ 
 $R_{11}$ 
 $R_{11}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{12}$ 
 $R_{13}$ 
 $R_{14}$ 
 $R_{15}$ 
 $R$ 

wherein R<sub>9</sub>, R<sub>10</sub>, R<sub>11</sub>, R<sub>12</sub>, R<sub>13</sub>, and R<sub>14</sub> are each, independently, hydrogen or a lower alkyl of 1-6 carbon atoms;

 $R_6$ , and  $R_7$  are each, independently, hydrogen, lower alkyl of 1-6 carbon atoms, or  $CH_2COOR_8$ , where  $R_8$  is a lower alkyl of 1-6 carbon atoms; and

X is O or S;

R<sub>1</sub> is hydrogen or a lower alkyl of 1-6 carbon atoms;

R<sub>2</sub>, R<sub>3</sub>, and R<sub>4</sub> are each, independently, hydrogen or halogen; and

R<sub>5</sub> is a lower alkyl of 1-6 carbon atoms;

or a pharmaceutically acceptable salt thereof in association or combination with a pharmaceutically acceptable carrier.